AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework
Open Access
- 9 March 2026
- journal article
- review article
- Published by JMIR Publications Inc. in JMIR AI
- Vol. 5 (1) , e86960
Abstract
Background: Type 2 diabetes mellitus (T2D) is a rapidly growing global health concern requiring innovative treatment methods. Ozempic (semaglutide), a glucagon-like peptide-1 receptor agonist, has proven consistent effectiveness in lowering blood glucose levels, supporting weight loss, and minimizing cardiovascular complications. In parallel, artificial intelligence (AI) elevates diabetes care yet complements these efforts by converting raw data from wearable devices, electronic health records, and medical imaging into practical insights for efficient, tailored, and customized treatment plans. Objective: The objective of this systematic review is to examine current evidence of AI-driven methods to optimize Ozempic-based T2D therapy. Methods: A total of 18 peer-reviewed articles were identified, revealing four dominant thematic clusters: (1) patient stratification and risk prediction, (2) AI-enhanced imaging for body composition changes, (3) cardiovascular and metabolic risk assessment, and (4) personalized AI-driven dosage. Results: Across multiple metrics, such as glycated hemoglobin reduction, weight loss, cardiovascular benefits, and adverse event mitigation, AI-based approaches outperformed standard fixed-dose regimens. A theoretical framework is proposed for AI-Ozempic integration, with continuous data collection, AI processing, clinical decision support, real-time support, and real-time feedback and modeling iteration refinement cycles. Conclusions: Significant gaps remain a persistent challenge, including the need for large-scale randomized controlled trials, longer follow-up periods, explainable AI models, regulatory validation, and practical strategies for routine clinical implementation. The findings emphasize the AI’s potential to transform semaglutide therapy while delineating important paths for future research.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trialsObesity, 2024
- Cluster of differentiation molecules in the metabolic syndromeClinica Chimica Acta, 2024
- Advancements in risk stratification and management strategies in primary cardiovascular preventionAtherosclerosis, 2024
- GLP-1 Agonists for Obesity—A New Recipe for Success?JAMA, 2024
- Diabetes mellitus, the fastest growing global public health concern: Early detection should be focusedHealth Science Reports, 2024
- Achieving Good Metabolic Control Without Weight Gain with the Systematic Use of GLP-1-RAs and SGLT-2 Inhibitors in Type 2 Diabetes: A Machine-learning Projection Using Data from Clinical PracticeClinical Therapeutics, 2023
- NAFLD and NASH: The Metabolically Diseased Liver2021
- Type II diabetes mellitus: a review on recent drug based therapeuticsBiomedicine & Pharmacotherapy, 2020
- Adherence to Therapies in Patients with Type 2 DiabetesDiabetes Therapy, 2013
- Support-vector networksMachine Learning, 1995